HEALTHY BRAIN AGEING (HeBA)- a European online project to identify subjects at risk for neurodegenerative disorders for further follow-upLocal Sub-Title: Gesund Altern!– eine populations- und internetbasierte Studie zu Früherkennungsmöglichkeiten des idiopathischen Parkinson-Syndroms und dementieller Syndrome

Conditions: G20
G30.9
Parkinson disease
Alzheimer disease, unspecified

Registration Number: DRKS00025979

Lead Sponsor: Paracelsus-Elena-Klinik Kassel

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Enrolling by invitation

Sex: All

Target Recruitment: 900

Inclusion Criteria

Phase 1a (Online Survey):
(a)registered residents of the city of Kassel and the district of Kassel
(b)male or female age 50 till 80
(c)consent to study participation via WebConsent form

Phase 1b (Smell Assessment)
(a)participants of phase 1 with highest risk according to the screening algorithm with subjective hyposmia (n=600) or subjective normosmia (n=2000)
(b)consent to be contacted by the study team for follow-up investigation via WebConsent form

Phase 2 (In-Person Visits)
(a)participants of phase 1a with lowest risk according to the risk assessment of the online survey
(b)participants of phase 1b with pathological olfactory function test (defined as at or below the 15th percentile by age and gender determined by UPSIT®)
(c)consent to be contacted by the study team for invitation to in-person investigations via WebConsent form
(d)written informed consent to participate in more in-depth examinations after consultation at the beginning of the in-person visit

Exclusion Criteria

Phase 1a (Online Survey)
(a)lack of consent

Phase 1b (Smell Assessment)
(a)subjects with previously diagnosed movement disorder (idiopathic or atypical PD) or diagnosed dementia
(b)subjects with clinically relevant diseases of the central nervous system (multiple sclerosis, severe vascular encephalopathy, Korsakoff syndrome, etc.)
(c)subjects who take medication that can cause drug-induced PD (e.g. Haloperidol, Risperdal, etc.)

Phase 2 (In-Person Visits)
(a)subjects with previously diagnosed movement disorder (idiopathic or atypical PD) or diagnosed dementia or high clinical suspicion of these conditions (in the opinion of the investigator)
b)subjects with clinically relevant diseases of the central nervous system (multiple sclerosis, severe vascular encephalopathy, Korsakoff syndrome, etc.) or high clinical suspicion of these conditions (in the opinion of the investigator)
c)subjects who take medication that can cause drug-induced PD (e.g. Haloperidol, Risperdal, etc.)
d)inability to provide written informed consent

Study & Design

Study Type: observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ONLINE SURVEY: The primary goal of phase 1a is the questionnaire-based characterization of the general population between the ages of 50 and 80 with regard to risk factors for prodromal PD and/or dementia.<br><br>SMELL ASSESSMENT: The primary goal of phase 1b is the additional characterization of olfactory function of subjects with highest risk according to the results of phase 1a.<br><br>IN-PERSON VISITS: The primary goal of phase 2 is the evaluation of the screening module of phase 1a with regard to specificity / validity, if necessary, optimization of the module.<br>

Secondary Outcome Measures

Name	Time	Method
A secondary goal of phase 1a (online survey) is to identify a population-based high” and low” risk cohort with regard to the likelihood of developing PD and/or dementia using known algorithms (risk assessment).<br><br>A secondary goal of phase 1b (smell assessment) is to identify eligible subjects for in-person visits of phase 2 according to their olfactory function.<br><br>A secondary goal of phase 2 (in-person visits) is the clinical and diagnostic characterization of the population-based high” and low-risk cohort” as well as the establishment of a longitudinal cohort.